Clovis' $75M offering follows IPO, as pancreatic cancer candidate could carve out a niche
This article was originally published in Scrip
Executive Summary
Clovis Oncology, which went public in November, now has proposed to raise an additional $75 million in a follow-on underwritten by JPMorgan, Credit Suisse and Leerink Swann.